China-Based Biopharmaceutical Company Dedicated to Bringing the Best-in-Class Drugs to Chinese Patients
JI (Shanghai) Biotech Co., Ltd. is a privately held oncology company headquartered in Shanghai, China. We are facilitating the development of crenolanib in China with Arog Pharmaceuticals, Inc, a U.S. based biotech who obtained global rights to crenolanib from Pfizer in 2010. JI (Shanghai) Biotech plans on participating in Arog’s global development plan by conducting local arms of its Ph. III studies in AML and, potentially, solid tumors (e.g., R/R Gastric Cancer, Gastrointestinal Stromal Tumor (GIST) and Glioblastoma).
We are facilitating the introduction of oncology drugs that are in clinical development in the US and Europe to China to meet the unmet needs of patients with advanced cancers and to shorten the gap between China and US in the pace of drug approval.
|Indication||Patient subset||Phase I||Phase II||Phase III|
|AML||Relapsed/Refractory (2L & 3L)||NCT03250338|
|Newly Diagnosed (1L)||NCT03258931|
|Solid Tumor Pipeline|
|GIST||PDGFRa D842V mutated||NCT02847429|
Opportunities with Crenolanib, an Oral Pan-FLT3 and PDGFR TKI
Crenolanib is an oral, highly potent and selective Type-1 pan-FLT3, PDGFRα, and PDGFRβ inhibitor with best-in-class potential in multiple oncology indications. Crenolanib has been evaluated in over 15 completed and ongoing clinical trials in over 500 patients, demonstrating promising clinical benefit and safety in multiple indications.
Development Opportunities with Ocaratuzumab, a Next Generation CD-20 mAb
JI (Shanghai) Biotech also anticipates facilitating the development of ocaratuzumab, a next-generation anti-CD20 monoclonal antibody, in China. Ocaratuzumab is fully engineered and has compelling early data in the treatment of B-cell malignancies in clinical trials. Clinical trials for the treatment of non-oncology indications are also contemplated.
Mentrik Biotech is a U.S. based biotech who acquired exclusive global rights to ocaratuzumab from Eli Lilly.